Results 221 to 230 of about 13,195 (282)

Decoding the Hexosamine Biosynthesis Pathway: Implications for Novel Therapeutic Strategies in Sarcoma

open access: yesJournal of Cellular Physiology, Volume 241, Issue 5, May 2026.
ABSTRACT Cancer cells rewire their metabolism to sustain a high proliferation rate. Sensing external cues is essential to match the metabolic fluxes of the cells to the external stimuli. As part of the glucose metabolism, the hexosamine biosynthesis pathway (HBP) is considered a nutrient‐sensing pathway. The HBP produces UDP‐GlcNAc, a key precursor for
Pegah Rahimizadeh   +4 more
wiley   +1 more source

A Syndecan‐Based Genetic Approach to Coat the Surface of Small Extracellular Vesicles With Nanobodies

open access: yesJournal of Extracellular Biology, Volume 5, Issue 5, May 2026.
ABSTRACT Small extracellular vesicles (sEVs) are promising vehicles for targeted therapeutic delivery, but strategies for their surface functionalization remain limited. Here, we present a reliable and simple genetic approach that enables customized modification of sEV surfaces and supports enhanced sEV uptake by recipient cells. This strategy is based
Lukas Hyka   +7 more
wiley   +1 more source

Small Molecule Inhibition of Mononegavirales RNA Polymerases

open access: yesJournal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT The order Mononegavirales includes several non‐segmented negative‐sense RNA viruses that are significant human pathogens, whose transcription and replication depend on multifunctional RNA‐dependent RNA polymerase (L protein). Recent discoveries in cryo‐electron microscopy (cryo‐EM) have elucidated the structures of these polymerases and their ...
Claire R. Cao   +3 more
wiley   +1 more source

Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions

open access: yesMedComm, Volume 7, Issue 5, May 2026.
We systematically summarized the etiologies, diagnostic approaches, and pathogenic mechanisms of liver fibrosis. Also, the therapeutic interventions for liver fibrosis were systematically classified into two main categories: etiological treatment and mechanism‐based antifibrotic therapies.
Jiaorong Qu   +8 more
wiley   +1 more source

Discovery of the First Potent DYRK2 Proteolysis Targeting Chimera Degraders. [PDF]

open access: yesACS Med Chem Lett
Chen J   +5 more
europepmc   +1 more source

Fusion Molecules Between the STAT5b Inhibitor Stafib‐2‐CR and a Cereblon Ligand

open access: yesChemistryOpen, Volume 15, Issue 5, May 2026.
The design and synthesis of fusion molecules between the selective STAT5b inhibitor Stafib‐2‐CR and a ligand of the E3 ubiquitin ligase cereblon is reported. Activity analysis in fluorescence polarization assays and isothermal titration calorimetry indicated that the chosen attachment point for the linker is well‐suited to retain activity of the fusion
Theresa Münzel   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy